For CLL, with higher numbers of patients relapsed on venetoclax, BCL2 mutations have been more frequently observed, mostly after prolonged treatment duration [6, 7, 12–14]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.